vs
爵士制药（JAZZ）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
爵士制药的季度营收约是Rollins, Inc.的1.3倍（$1.2B vs $906.4M），爵士制药净利率更高（17.0% vs 11.9%，领先5.1%），Rollins, Inc.同比增速更快（10.2% vs 10.1%），爵士制药自由现金流更多（$345.8M vs $111.2M），过去两年爵士制药的营收复合增速更高（15.2% vs 0.8%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
JAZZ vs ROL — 直观对比
营收规模更大
JAZZ
是对方的1.3倍
$906.4M
营收增速更快
ROL
高出0.1%
10.1%
净利率更高
JAZZ
高出5.1%
11.9%
自由现金流更多
JAZZ
多$234.6M
$111.2M
两年增速更快
JAZZ
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $906.4M |
| 净利润 | $203.5M | $107.8M |
| 毛利率 | — | — |
| 营业利润率 | 21.2% | 16.1% |
| 净利率 | 17.0% | 11.9% |
| 营收同比 | 10.1% | 10.2% |
| 净利润同比 | 6.5% | 2.5% |
| 每股收益（稀释后） | $3.34 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $1.2B | $912.9M | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | $999.5M | ||
| Q1 25 | $897.8M | $822.5M | ||
| Q4 24 | $1.1B | $832.2M | ||
| Q3 24 | $1.1B | $916.3M | ||
| Q2 24 | $1.0B | $891.9M |
净利润JAZZROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $203.5M | $116.4M | ||
| Q3 25 | $251.4M | $163.5M | ||
| Q2 25 | $-718.5M | $141.5M | ||
| Q1 25 | $-92.5M | $105.2M | ||
| Q4 24 | $191.1M | $105.7M | ||
| Q3 24 | $215.1M | $136.9M | ||
| Q2 24 | $168.6M | $129.4M |
营业利润率JAZZROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | 21.2% | 17.5% | ||
| Q3 25 | 5.1% | 21.9% | ||
| Q2 25 | -65.6% | 19.8% | ||
| Q1 25 | -6.2% | 17.3% | ||
| Q4 24 | 17.5% | 18.1% | ||
| Q3 24 | 24.7% | 20.9% | ||
| Q2 24 | 19.5% | 20.4% |
净利率JAZZROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | 17.0% | 12.8% | ||
| Q3 25 | 22.3% | 15.9% | ||
| Q2 25 | -68.7% | 14.2% | ||
| Q1 25 | -10.3% | 12.8% | ||
| Q4 24 | 17.6% | 12.7% | ||
| Q3 24 | 20.4% | 14.9% | ||
| Q2 24 | 16.5% | 14.5% |
每股收益（稀释后）JAZZROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $3.34 | $0.24 | ||
| Q3 25 | $4.08 | $0.34 | ||
| Q2 25 | $-11.74 | $0.29 | ||
| Q1 25 | $-1.52 | $0.22 | ||
| Q4 24 | $2.97 | $0.22 | ||
| Q3 24 | $3.42 | $0.28 | ||
| Q2 24 | $2.49 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $116.5M |
| 总债务越低越好 | $5.4B | $650.6M |
| 股东权益账面价值 | $4.3B | $1.4B |
| 总资产 | $11.7B | $3.2B |
| 负债/权益比越低杠杆越低 | 1.24× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资JAZZROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $1.4B | $100.0M | ||
| Q3 25 | $1.3B | $127.4M | ||
| Q2 25 | $1.2B | $123.0M | ||
| Q1 25 | $1.9B | $201.2M | ||
| Q4 24 | $2.4B | $89.6M | ||
| Q3 24 | $2.2B | $95.3M | ||
| Q2 24 | $1.4B | $106.7M |
总债务JAZZROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | $5.4B | $486.1M | ||
| Q3 25 | $5.4B | $485.7M | ||
| Q2 25 | $5.4B | $485.3M | ||
| Q1 25 | $5.4B | $485.5M | ||
| Q4 24 | $6.1B | $395.3M | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — |
股东权益JAZZROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $4.3B | $1.4B | ||
| Q3 25 | $4.0B | $1.5B | ||
| Q2 25 | $3.7B | $1.4B | ||
| Q1 25 | $4.2B | $1.4B | ||
| Q4 24 | $4.1B | $1.3B | ||
| Q3 24 | $4.2B | $1.3B | ||
| Q2 24 | $3.8B | $1.2B |
总资产JAZZROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $11.7B | $3.1B | ||
| Q3 25 | $11.4B | $3.2B | ||
| Q2 25 | $10.9B | $3.2B | ||
| Q1 25 | $11.5B | $2.9B | ||
| Q4 24 | $12.0B | $2.8B | ||
| Q3 24 | $12.3B | $2.8B | ||
| Q2 24 | $11.4B | $2.8B |
负债/权益比JAZZROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | 1.24× | 0.35× | ||
| Q3 25 | 1.35× | 0.32× | ||
| Q2 25 | 1.45× | 0.34× | ||
| Q1 25 | 1.29× | 0.36× | ||
| Q4 24 | 1.49× | 0.30× | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $111.2M |
| 自由现金流率自由现金流/营收 | 28.9% | 12.3% |
| 资本支出强度资本支出/营收 | 1.4% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.78× | 1.10× |
| 过去12个月自由现金流最近4个季度 | $1.3B | $621.1M |
8季度趋势，按日历期对齐
经营现金流JAZZROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $362.5M | $164.7M | ||
| Q3 25 | $474.6M | $191.3M | ||
| Q2 25 | $88.9M | $175.1M | ||
| Q1 25 | $429.8M | $146.9M | ||
| Q4 24 | $398.6M | $188.2M | ||
| Q3 24 | $398.7M | $146.9M | ||
| Q2 24 | $331.4M | $145.1M |
自由现金流JAZZROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $345.8M | $159.0M | ||
| Q3 25 | $459.4M | $182.8M | ||
| Q2 25 | $75.9M | $168.0M | ||
| Q1 25 | $415.9M | $140.1M | ||
| Q4 24 | $385.3M | $184.0M | ||
| Q3 24 | $388.0M | $139.4M | ||
| Q2 24 | $324.3M | $136.4M |
自由现金流率JAZZROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 28.9% | 17.4% | ||
| Q3 25 | 40.8% | 17.8% | ||
| Q2 25 | 7.3% | 16.8% | ||
| Q1 25 | 46.3% | 17.0% | ||
| Q4 24 | 35.4% | 22.1% | ||
| Q3 24 | 36.8% | 15.2% | ||
| Q2 24 | 31.7% | 15.3% |
资本支出强度JAZZROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 1.4% | 0.6% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 1.2% | 0.7% | ||
| Q1 25 | 1.5% | 0.8% | ||
| Q4 24 | 1.2% | 0.5% | ||
| Q3 24 | 1.0% | 0.8% | ||
| Q2 24 | 0.7% | 1.0% |
现金转化率JAZZROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | 1.78× | 1.41× | ||
| Q3 25 | 1.89× | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | 2.09× | 1.78× | ||
| Q3 24 | 1.85× | 1.07× | ||
| Q2 24 | 1.97× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
ROL
暂无分部数据
